Study Evaluating the Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500

Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00518492

Enrollment

Registered

2007-08-20

Start date

2007-08-31

Completion date

2008-04-30

Last updated

2009-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Upon completion of participation in the 6108A1-500 study, subjects will be asked to consent for this duration of immunity study to provide up to two additional blood samples. SBA & IgG testing will be done on these samples taken at 6 & 12 months. The sites participating in this duration of immunity study are the same sites participating in the 6108A1-500 study.

Interventions

PROCEDUREBlood Sampling

Blood draws at 6 and 12 months following end of 6108A1-500 trial.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 25 Years

Healthy volunteers

Yes

Inclusion criteria

* Completed study 6108A1-500 (three doses administered and visit 9 completed).

Exclusion criteria

* Bleeding diathesis or condition associated with prolonged bleeding time. * Any clinically significant chronic disease that, in the investigators judgment may be worsened by blood draw.

Design outcomes

Primary

Measure	Time frame
Immunogenicity at 6 and 12 months post 6108A1-500 study.	6 and 12 months

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026